Index
RUT
Market Cap
3.10B
Enterprise Value
3.20B
Income
-6.50M
Sales
368.26M
Book/sh
0.27
Cash/sh
0.72
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
435
IPO
Jun 21, 2018
P/E
-
Forward P/E
40.40
PEG
-
P/S
8.42
P/B
63.51
P/C
23.65
P/FCF
42.69
EV/EBITDA
53.60
EV/Sales
8.68
Quick Ratio
1.58
Current Ratio
2.15
Debt/Eq
4.63
LT Debt/Eq
4.50
Option/Short
Yes / Yes
EPS (ttm)
-0.05
EPS next Y
0.42
EPS next Q
0.07
EPS this Y
-661.27%
EPS next Y
2433.33%
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
38.33% 70.20%
EPS Y/Y TTM
63.43%
Sales Y/Y TTM
38.37%
EPS Q/Q
1597.14%
Sales Q/Q
44.16%
Insider Own
5.05%
Insider Trans
-4.55%
Inst Own
62.76%
Inst Trans
1.20%
ROA
-1.64%
ROE
-27.11%
ROIC
-2.42%
Gross Margin
84.44%
Oper. Margin
12.70%
Profit Margin
-1.76%
SMA20
22.25%
SMA50
50.32%
SMA200
110.27%
Trades
Shs Outstand
182.57M
Shs Float
173.47M
52W High
17.28 -1.79%
52W Low
5.25 223.24%
Volatility
3.28% 4.82%
ATR (14)
0.69
RSI (14)
81.66
Beta
0.55
Rel Volume
1.01
Avg Volume
2.83M
Volume
2,857,245
Perf Week
1.86%
Perf Month
56.26%
Perf Quarter
94.16%
Perf Half Y
174.15%
Perf YTD
116.18%
Perf Year
148.10%
Perf 3Y
832.42%
Perf 5Y
647.58%
Perf 10Y
-
Prev Close
16.62
Price
16.97
Change %
2.11%
Analysts 9 incl. previous ratings
Rating Distribution 8 Buy · 1 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Dec 09, 2025 Initiated B Barclays
Overweight $9 -47.0% Aug 12, 2025 Resumed H H.C. Wainwright
Buy $10 -41.1% Nov 11, 2024 Downgrade P Piper Sandler
Overweight → Neutral $3 -82.3% Mar 28, 2024 Initiated O Oppenheimer
Outperform $5 -70.5% Aug 28, 2023 Initiated C Craig Hallum
Buy $4.50 -73.5% Oct 21, 2022 Initiated J Jefferies
Buy $4 -76.4% Apr 28, 2022 Initiated C Craig Hallum
Buy $6.50 -61.7% Nov 17, 2021 Initiated S SVB Leerink
Outperform $6 -64.6% Oct 29, 2021 Initiated H H.C. Wainwright
Buy $4 -76.4% Apr 07, 2021 Resumed R RBC Capital Mkts
Outperform $11 -35.2% Feb 18, 2020 Initiated P Piper Sandler
Overweight $12 -29.3% Jul 16, 2018 Initiated R RBC Capital Mkts
Outperform $24 +41.4% Jul 16, 2018 Initiated L Leerink Partners
Outperform $24 +41.4% Jul 16, 2018 Initiated J Jefferies
Buy $23 +35.5%
Show Previous Ratings
Nov-11-26 10:49PM
01:23PM
Nov-08-26 11:13PM
Nov-05-26 11:16AM
(Earnings Whispers)
+25.05%
08:55AM
07:27AM
Loading…
07:27AM
07:00AM
Nov-02-26 07:00AM
Oct-28-26 05:56PM
Oct-22-26 08:00AM
Oct-15-26 08:00AM
Oct-02-26 05:00PM
Sep-29-26 04:17PM
02:01PM
Aug-26-26 07:30AM
07:13PM
Loading…
Aug-06-26 07:13PM
(GuruFocus.com)
-9.25%
+7.74%
07:18AM
07:00AM
Jul-23-26 07:30AM
Jul-02-26 04:05PM
Jun-30-26 07:00AM
Jun-11-26 04:39PM
07:00AM
May-07-26 07:18AM
(Associated Press)
+4.08%
07:00AM
Apr-23-26 07:30AM
Apr-03-26 04:15PM
Mar-02-26 04:01PM
10:37AM
09:30AM
08:06AM
Loading…
08:06AM
07:13AM
(Associated Press Finance)
07:00AM
Feb-27-26 12:29PM
Feb-26-26 05:55PM
12:15PM
09:15AM
05:35AM
Feb-17-26 07:30AM
Jan-08-26 07:00AM
Jan-02-26 04:15PM
(Business Wire)
-6.37%
-3.54%
Dec-31-25 07:09PM
Dec-18-25 01:13PM
Dec-01-25 07:00AM
Nov-06-25 09:30AM
08:30AM
07:00AM
Oct-30-25 06:45PM
Oct-23-25 07:30AM
Oct-20-25 12:00PM
09:15AM
Oct-16-25 09:06AM
Oct-13-25 07:58AM
Oct-03-25 04:15PM
12:00PM
09:15AM
Sep-09-25 12:00PM
Aug-29-25 05:09AM
Aug-25-25 07:00AM
Aug-12-25 12:00PM
09:15AM
Aug-07-25 10:30AM
(Associated Press Finance)
+20.22%
09:30AM
08:35AM
07:32AM
(Associated Press Finance)
07:00AM
Jul-31-25 07:30AM
Jul-03-25 08:19AM
Jun-03-25 07:30AM
May-20-25 07:30AM
May-12-25 03:54PM
May-09-25 03:21AM
May-08-25 08:20AM
07:17AM
(Associated Press Finance)
07:00AM
May-07-25 12:08PM
11:51AM
May-05-25 05:30PM
May-01-25 07:00AM
Apr-22-25 06:46PM
Apr-17-25 07:00AM
Mar-28-25 08:00AM
Mar-27-25 10:18AM
Mar-20-25 10:13AM
Mar-19-25 04:49PM
Mar-17-25 08:00AM
Mar-07-25 02:08AM
Mar-06-25 09:30AM
08:15AM
07:22AM
(Associated Press Finance)
07:00AM
Feb-27-25 07:00AM
Feb-26-25 10:00AM
Feb-24-25 08:00AM
Feb-05-25 08:00AM
Jan-21-25 09:00AM
Jan-11-25 07:27AM
Jan-10-25 07:00AM
Jan-06-25 04:15PM
Nov-26-24 07:00AM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
McCulloch Kevin See Remarks Nov 05 '26 Sale 12.49 25,000 312,215 1,559,208 Nov 06 04:32 PM KEVIN MCCULLOCH Officer Nov 05 '26 Proposed Sale 10.46 25,000 261,500 Nov 05 04:31 PM Pieper Steven See Remarks Nov 02 '26 Sale 10.23 5,000 51,174 1,346,053 Nov 04 04:58 PM Hecht Beth See Remarks Nov 02 '26 Sale 10.23 25,000 255,828 1,086,130 Nov 04 04:57 PM McCulloch Kevin See Remarks Nov 02 '26 Sale 10.23 15,000 153,488 1,584,208 Nov 04 04:57 PM BETH HECHT Officer Nov 02 '26 Proposed Sale 10.71 75,000 803,250 Nov 02 04:39 PM Pieper Steven See Remarks Oct 01 '26 Sale 9.41 5,000 47,036 1,351,053 Oct 02 04:54 PM McCulloch Kevin See Remarks Oct 01 '26 Sale 9.41 15,000 141,120 1,599,208 Oct 02 04:54 PM Hecht Beth See Remarks Oct 01 '26 Sale 9.41 16,666 156,792 1,111,130 Oct 02 04:54 PM BETH HECHT Officer Oct 01 '26 Proposed Sale 9.56 16,666 159,327 Oct 01 04:26 PM McCulloch Kevin See Remarks Sep 28 '26 Sale 10.00 25,000 250,000 1,614,208 Sep 29 04:59 PM KEVIN MCCULLOCH Officer Sep 28 '26 Proposed Sale 9.10 70,000 637,000 Sep 28 04:19 PM McCulloch Kevin See Remarks Sep 01 '26 Sale 8.49 15,000 127,308 1,639,208 Sep 01 06:21 PM Hecht Beth See Remarks Sep 01 '26 Sale 8.49 16,666 141,434 1,127,796 Sep 01 06:21 PM Pieper Steven See Remarks Sep 01 '26 Sale 8.50 5,000 42,500 1,356,053 Sep 01 06:20 PM Pieper Steven See Remarks Aug 12 '26 Sale 8.50 5,000 42,500 1,361,053 Aug 12 04:44 PM STEVEN PIEPER Officer Aug 12 '26 Proposed Sale 8.39 20,000 167,800 Aug 12 04:37 PM McCulloch Kevin See Remarks Aug 03 '26 Sale 8.02 15,000 120,240 1,676,126 Aug 04 05:30 PM Hecht Beth See Remarks Aug 03 '26 Sale 8.01 16,666 133,553 1,144,462 Aug 04 05:16 PM Pieper Steven See Remarks Jul 07 '26 Sale 8.52 27,600 235,276 1,366,053 Jul 07 05:11 PM Pieper Steven See Remarks Jul 06 '26 Sale 8.50 17,400 147,900 1,393,653 Jul 07 05:11 PM STEVEN PIEPER Officer Jul 07 '26 Proposed Sale 8.37 27,600 231,012 Jul 07 04:37 PM STEVEN PIEPER Officer Jul 06 '26 Proposed Sale 8.28 17,400 144,072 Jul 06 04:39 PM McCulloch Kevin See Remarks Jul 01 '26 Sale 8.03 90,000 722,511 1,691,126 Jul 02 04:40 PM Hecht Beth See Remarks Jul 01 '26 Sale 8.03 16,666 133,860 1,161,128 Jul 02 04:38 PM BETH HECHT Officer Jul 01 '26 Proposed Sale 7.92 49,998 395,984 Jul 01 04:51 PM KEVIN MCCULLOCH Officer Jul 01 '26 Proposed Sale 7.92 120,000 950,400 Jul 01 04:21 PM PERSKY MARLA Director Jun 03 '26 Sale 5.90 15,500 91,433 126,500 Jun 05 06:29 PM HALKUFF DAWN Director Jun 04 '26 Sale 6.09 20,000 121,886 95,000 Jun 05 06:18 PM BORMANN-KENNEDY BARBARA-JEAN A Director Jun 04 '26 Sale 6.09 16,000 97,507 126,500 Jun 05 06:18 PM JOHNSON JOHN Director Jun 04 '26 Sale 6.09 15,000 91,422 683,083 Jun 05 06:17 PM DAWN HALKUFF Director Jun 04 '26 Proposed Sale 5.89 20,000 117,800 Jun 04 04:33 PM JOHN H JOHNSON Director Jun 04 '26 Proposed Sale 5.89 15,000 88,350 Jun 04 04:33 PM Barbara-Jean Bormann-Kennedy Director Jun 04 '26 Proposed Sale 5.89 16,000 94,240 Jun 04 04:32 PM MARLA PERSKY Director Jun 03 '26 Proposed Sale 6.00 15,500 93,000 Jun 03 04:25 PM Hecht Beth See Remarks Jun 01 '26 Sale 6.06 16,667 100,982 1,176,506 Jun 02 06:05 PM Hecht Beth See Remarks May 01 '26 Sale 6.23 16,667 103,805 1,193,173 May 01 05:50 PM Hecht Beth See Remarks Apr 01 '26 Sale 5.99 16,667 99,859 1,209,840 Apr 03 05:45 PM Brady James Aloysius Director Mar 30 '26 Sale 5.54 10,834 60,036 89,166 Apr 01 05:54 PM JAMES BRADY Director Mar 30 '26 Proposed Sale 5.40 10,834 58,504 Mar 30 05:31 PM McCulloch Kevin See Remarks Mar 12 '26 Option Exercise 4.09 48,898 199,992 1,777,725 Mar 16 06:11 PM Pieper Steven See Remarks Mar 05 '26 Option Exercise 4.71 41,927 197,308 1,408,940 Mar 05 07:18 PM Hecht Beth See Remarks Mar 02 '26 Sale 6.25 16,667 104,086 1,226,507 Mar 04 05:28 PM BETH HECHT Officer Mar 02 '26 Proposed Sale 6.12 66,668 408,008 Mar 02 04:36 PM Hecht Beth See Remarks Feb 02 '26 Sale 7.45 16,667 124,147 1,243,174 Feb 02 06:11 PM McCulloch Kevin See Remarks Jan 08 '26 Sale 8.00 15,000 120,000 1,685,426 Jan 09 05:34 PM KEVIN MCCULLOCH Officer Jan 08 '26 Proposed Sale 7.21 60,000 432,600 Jan 08 04:22 PM Shannon John Patrick Jr See Remarks Jan 05 '26 Option Exercise 1.63 92,301 149,998 2,797,647 Jan 06 06:14 PM Shannon John Patrick Jr See Remarks Jan 05 '26 Sale 7.08 24,907 176,257 2,705,346 Jan 06 06:14 PM Hecht Beth See Remarks Jan 02 '26 Sale 7.43 16,667 123,776 1,308,103 Jan 05 06:01 PM JOHN H JOHNSON Director Dec 19 '25 Proposed Sale 7.22 135,402 977,034 Dec 19 06:15 PM JOHNSON JOHN Director Dec 19 '25 Sale 7.22 135,400 977,019 698,083 Dec 19 05:17 PM BORMANN-KENNEDY BARBARA-JEAN A Director Dec 12 '25 Sale 7.09 15,000 106,414 142,500 Dec 15 05:24 PM BARBARA-JEAN A BORMANN-KENNEDY Director Dec 12 '25 Proposed Sale 7.01 15,000 105,150 Dec 12 04:20 PM Hecht Beth See Remarks Dec 01 '25 Sale 7.01 16,667 116,781 1,320,176 Dec 02 05:14 PM
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Chairman & CEO Mr. John P. Shannon
President & COO Mr. Kevin McCulloch
Chief Financial Officer Mr. Steven M. Pieper
Chief Legal Officer & Corporate Secretary Ms. Beth P. Hecht J.D.
M.D. Dr. Anh T. Nguyen M.B.A.